+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type- Product Image
Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type- Product Image
New

Migraine Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 95 Pages
  • May 2025
  • Region: Global
  • Prof Research
  • ID: 5922786
Description Jump to:
Migraine drugs, including CGRP inhibitors, triptans, and neurotoxins, address a prevalent neurological disorder affecting 1 billion people globally, with a 14% prevalence rate, particularly impacting women (18% vs. 10% in men). The market is driven by the significant disability burden, with migraines causing 2.2% of global disease burden, and the advent of CGRP-based therapies, which reduce attack frequency by over 50%. Lifestyle factors like stress, sleep deprivation, and dietary triggers exacerbate migraines, while improved diagnosis and female-specific treatments boost demand. The global migraine drugs market is estimated at USD 4.0-7.0 billion in 2025, with a CAGR of 8%-13% through 2030.

Regional Market Trends

  • North America: The U.S. leads with advanced neurology care and CGRP adoption, while Canada focuses on headache clinics.
  • Europe: Germany, France, and the UK drive growth with high diagnosis rates and reimbursement.
  • Asia Pacific: China and India see rising demand due to urban stress, with Japan emphasizing CGRP therapies.
  • Rest of the World: Brazil expands access to generics, while the Middle East addresses women’s health.

Application Analysis

  • Pediatric: Expected growth of 7.8%-12.8%, driven by rising diagnoses. Trends focus on non-drug therapies.
  • Adult: Projected growth of 8.5%-13.5%, linked to high prevalence. Advances emphasize CGRP inhibitors.
  • Geriatric: Anticipated growth of 7.5%-12.5%, tied to comorbidities. Trends highlight low-dose options.

Type Analysis

  • CGRP Monoclonal Antibodies: Expected growth of 9.0%-14.0%, valued for chronic migraine prevention. Trends focus on long-term efficacy.
  • CGRP Small Molecule Antagonists: Projected growth of 8.8%-13.8%, suited for acute relief. Advances emphasize oral delivery.
  • Acetylcholine Inhibitors/Neurotoxins: Anticipated growth of 8.0%-13.0%, used for resistant cases. Trends highlight Botox applications.
  • Triptans: Expected growth of 7.5%-12.5%, critical for acute attacks. Trends focus on generics.
  • Ditans: Expected growth of 8.2%-13.2%, emerging for acute treatment. Developments prioritize tolerability.
  • Ergot Alkaloids: Expected growth of 7.0%-12.0%, used in niche cases. Trends highlight limited use.
  • NSAIDs: Expected growth of 7.2%-12.2%, suited for mild attacks. Trends focus on OTC options.
  • Others: Expected growth of 6.8%-11.8%, covering novel therapies. Trends highlight non-drug devices.

Key Market Players

  • Pfizer: Offers triptans for acute migraine relief.
  • Eli Lilly: Develops CGRP monoclonal antibodies.
  • Amgen: Provides preventive CGRP therapies.
  • Teva Pharmaceutical: Supplies generic triptans.
  • GSK: Focuses on acute migraine treatments.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Moderate, due to high R&D costs, but generics lower barriers.
  • Threat of Substitutes: Moderate, with non-drug therapies competing, but drugs remain primary.
  • Bargaining Power of Buyers: Moderate, as patients seek effective options, but CGRP therapies limit choices.
  • Bargaining Power of Suppliers: Low, with multiple API providers.
  • Competitive Rivalry: High, with players competing on efficacy and delivery.

Market Opportunities and Challenges

Opportunities:

  • Addressing migraines, affecting 1 billion people globally.
  • Leveraging CGRP inhibitors, reducing attacks by 50%.
  • Utilizing increased diagnosis rates, up to 60% in high-income countries.
  • Meeting demand driven by stress and sleep issues.
  • Supporting women, with 18% prevalence, through targeted therapies.
  • Expanding non-drug options like Nerivio.

Challenges:

  • High costs of CGRP therapies.
  • Regulatory delays for novel drugs.
  • Patient adherence issues with preventive treatments.
  • Competition from generics and non-drug therapies.
  • Limited access in low-income regions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Migraine Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Migraine Drug Market in North America (2020-2030)
8.1 Migraine Drug Market Size
8.2 Migraine Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Migraine Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Migraine Drug Market in South America (2020-2030)
9.1 Migraine Drug Market Size
9.2 Migraine Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Migraine Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Migraine Drug Market in Asia & Pacific (2020-2030)
10.1 Migraine Drug Market Size
10.2 Migraine Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Migraine Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Migraine Drug Market in Europe (2020-2030)
11.1 Migraine Drug Market Size
11.2 Migraine Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Migraine Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Migraine Drug Market in MEA (2020-2030)
12.1 Migraine Drug Market Size
12.2 Migraine Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Migraine Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Migraine Drug Market (2020-2025)
13.1 Migraine Drug Market Size
13.2 Migraine Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Migraine Drug Market Size by Type
Chapter 14 Global Migraine Drug Market Forecast (2025-2030)
14.1 Migraine Drug Market Size Forecast
14.2 Migraine Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Migraine Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Pfizer
15.1.1 Company Profile
15.1.2 Main Business and Migraine Drug Information
15.1.3 SWOT Analysis of Pfizer
15.1.4 Pfizer Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.2 Eli Lilly
15.2.1 Company Profile
15.2.2 Main Business and Migraine Drug Information
15.2.3 SWOT Analysis of Eli Lilly
15.2.4 Eli Lilly Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.3 Amgen
15.3.1 Company Profile
15.3.2 Main Business and Migraine Drug Information
15.3.3 SWOT Analysis of Amgen
15.3.4 Amgen Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.4 Teva Pharmaceutical
15.4.1 Company Profile
15.4.2 Main Business and Migraine Drug Information
15.4.3 SWOT Analysis of Teva Pharmaceutical
15.4.4 Teva Pharmaceutical Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.5 GSK
15.5.1 Company Profile
15.5.2 Main Business and Migraine Drug Information
15.5.3 SWOT Analysis of GSK
15.5.4 GSK Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.6 AbbVie
15.6.1 Company Profile
15.6.2 Main Business and Migraine Drug Information
15.6.3 SWOT Analysis of AbbVie
15.6.4 AbbVie Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.7 Bausch Health
15.7.1 Company Profile
15.7.2 Main Business and Migraine Drug Information
15.7.3 SWOT Analysis of Bausch Health
15.7.4 Bausch Health Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.8 Impel Pharmaceuticals
15.8.1 Company Profile
15.8.2 Main Business and Migraine Drug Information
15.8.3 SWOT Analysis of Impel Pharmaceuticals
15.8.4 Impel Pharmaceuticals Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.9 Currax Pharmaceuticals
15.9.1 Company Profile
15.9.2 Main Business and Migraine Drug Information
15.9.3 SWOT Analysis of Currax Pharmaceuticals
15.9.4 Currax Pharmaceuticals Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.10 Tonix Medicines
15.10.1 Company Profile
15.10.2 Main Business and Migraine Drug Information
15.10.3 SWOT Analysis of Tonix Medicines
15.10.4 Tonix Medicines Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.11 Lundbeck
15.11.1 Company Profile
15.11.2 Main Business and Migraine Drug Information
15.11.3 SWOT Analysis of Lundbeck
15.11.4 Lundbeck Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
15.12 Gensco Pharma
15.12.1 Company Profile
15.12.2 Main Business and Migraine Drug Information
15.12.3 SWOT Analysis of Gensco Pharma
15.12.4 Gensco Pharma Migraine Drug Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Migraine Drug Report
Table Data Sources of Migraine Drug Report
Table Major Assumptions of Migraine Drug Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Migraine Drug Picture
Table Migraine Drug Classification
Table Migraine Drug Applications
Table Drivers of Migraine Drug Market
Table Restraints of Migraine Drug Market
Table Opportunities of Migraine Drug Market
Table Threats of Migraine Drug Market
Table COVID-19 Impact For Migraine Drug Market
Table Raw Materials Suppliers
Table Different Production Methods of Migraine Drug
Table Cost Structure Analysis of Migraine Drug
Table Key End Users
Table Latest News of Migraine Drug Market
Table Merger and Acquisition
Table Planned/Future Project of Migraine Drug Market
Table Policy of Migraine Drug Market
Table 2020-2030 North America Migraine Drug Market Size
Figure 2020-2030 North America Migraine Drug Market Size and CAGR
Table 2020-2030 North America Migraine Drug Market Size by Application
Table 2020-2025 North America Migraine Drug Key Players Revenue
Table 2020-2025 North America Migraine Drug Key Players Market Share
Table 2020-2030 North America Migraine Drug Market Size by Type
Table 2020-2030 United States Migraine Drug Market Size
Table 2020-2030 Canada Migraine Drug Market Size
Table 2020-2030 Mexico Migraine Drug Market Size
Table 2020-2030 South America Migraine Drug Market Size
Figure 2020-2030 South America Migraine Drug Market Size and CAGR
Table 2020-2030 South America Migraine Drug Market Size by Application
Table 2020-2025 South America Migraine Drug Key Players Revenue
Table 2020-2025 South America Migraine Drug Key Players Market Share
Table 2020-2030 South America Migraine Drug Market Size by Type
Table 2020-2030 Brazil Migraine Drug Market Size
Table 2020-2030 Argentina Migraine Drug Market Size
Table 2020-2030 Chile Migraine Drug Market Size
Table 2020-2030 Peru Migraine Drug Market Size
Table 2020-2030 Asia & Pacific Migraine Drug Market Size
Figure 2020-2030 Asia & Pacific Migraine Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Migraine Drug Market Size by Application
Table 2020-2025 Asia & Pacific Migraine Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Migraine Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Migraine Drug Market Size by Type
Table 2020-2030 China Migraine Drug Market Size
Table 2020-2030 India Migraine Drug Market Size
Table 2020-2030 Japan Migraine Drug Market Size
Table 2020-2030 South Korea Migraine Drug Market Size
Table 2020-2030 Southeast Asia Migraine Drug Market Size
Table 2020-2030 Australia Migraine Drug Market Size
Table 2020-2030 Europe Migraine Drug Market Size
Figure 2020-2030 Europe Migraine Drug Market Size and CAGR
Table 2020-2030 Europe Migraine Drug Market Size by Application
Table 2020-2025 Europe Migraine Drug Key Players Revenue
Table 2020-2025 Europe Migraine Drug Key Players Market Share
Table 2020-2030 Europe Migraine Drug Market Size by Type
Table 2020-2030 Germany Migraine Drug Market Size
Table 2020-2030 France Migraine Drug Market Size
Table 2020-2030 United Kingdom Migraine Drug Market Size
Table 2020-2030 Italy Migraine Drug Market Size
Table 2020-2030 Spain Migraine Drug Market Size
Table 2020-2030 Belgium Migraine Drug Market Size
Table 2020-2030 Netherlands Migraine Drug Market Size
Table 2020-2030 Austria Migraine Drug Market Size
Table 2020-2030 Poland Migraine Drug Market Size
Table 2020-2030 Russia Migraine Drug Market Size
Table 2020-2030 MEA Migraine Drug Market Size
Figure 2020-2030 MEA Migraine Drug Market Size and CAGR
Table 2020-2030 MEA Migraine Drug Market Size by Application
Table 2020-2025 MEA Migraine Drug Key Players Revenue
Table 2020-2025 MEA Migraine Drug Key Players Market Share
Table 2020-2030 MEA Migraine Drug Market Size by Type
Table 2020-2030 Egypt Migraine Drug Market Size
Table 2020-2030 Israel Migraine Drug Market Size
Table 2020-2030 South Africa Migraine Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Migraine Drug Market Size
Table 2020-2030 Turkey Migraine Drug Market Size
Table 2020-2025 Global Migraine Drug Market Size by Region
Table 2020-2025 Global Migraine Drug Market Size Share by Region
Table 2020-2025 Global Migraine Drug Market Size by Application
Table 2020-2025 Global Migraine Drug Market Share by Application
Table 2020-2025 Global Migraine Drug Key Vendors Revenue
Figure 2020-2025 Global Migraine Drug Market Size and Growth Rate
Table 2020-2025 Global Migraine Drug Key Vendors Market Share
Table 2020-2025 Global Migraine Drug Market Size by Type
Table 2020-2025 Global Migraine Drug Market Share by Type
Table 2025-2030 Global Migraine Drug Market Size by Region
Table 2025-2030 Global Migraine Drug Market Size Share by Region
Table 2025-2030 Global Migraine Drug Market Size by Application
Table 2025-2030 Global Migraine Drug Market Share by Application
Table 2025-2030 Global Migraine Drug Key Vendors Revenue
Figure 2025-2030 Global Migraine Drug Market Size and Growth Rate
Table 2025-2030 Global Migraine Drug Key Vendors Market Share
Table 2025-2030 Global Migraine Drug Market Size by Type
Table 2025-2030 Migraine Drug Global Market Share by Type

Companies Mentioned

  • Pfizer
  • Eli Lilly
  • Amgen
  • Teva Pharmaceutical
  • GSK
  • AbbVie
  • Bausch Health
  • Impel Pharmaceuticals
  • Currax Pharmaceuticals
  • Tonix Medicines
  • Lundbeck
  • Gensco Pharma

Related Topics

Related Reports

Migraine Drugs Market Size, Share & Trends Analysis Report by Treatment (Acute, Preventive), Therapeutic Class, Route of Administration, Age Group (Pediatric, Adult, Geriatric), Availability, Region, with Growth Forecasts, 2025-2030 - Product Image

Migraine Drugs Market Size, Share & Trends Analysis Report by Treatment (Acute, Preventive), Therapeutic Class, Route of Administration, Age Group (Pediatric, Adult, Geriatric), Availability, Region, with Growth Forecasts, 2025-2030

  • Report
  • 159 Pages
  • Global
From
Migraine Drugs Market by Drug Class, Route of Administration, Distribution Channel, Indication, Patient Age Group - Global Forecast to 2030 - Product Image

Migraine Drugs Market by Drug Class, Route of Administration, Distribution Channel, Indication, Patient Age Group - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Migraine Drugs - Global Strategic Business Report - Product Image

Migraine Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Migraine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.